Thermo Fisher Scientific
Join thought leaders and peers at the proteomicsNOW virtual conference to learn about the latest advances in proteomics, share best practices, and explore new technologies and techniques designed to help improve your research results.
This event highlights recent developments in proteomics through live webinars, lightning talks, poster sessions, and panel discussions. Since we know how hard it is to set aside long periods of time to watch groundbreaking scientific talks, the event is available on demand as well.
Targeting the science of structural elucidation of proteins, the sessions cover the broad field of mass spectrometric applications in proteomics.
Presenter Name, Head of Mass Spectrometry, Proteomics Core
Dr. Liu is the head of the Mass Spectrometry and Proteomics Core Facility at the Leibniz-Institute for Molecular Pharmacology. Her lab focuses on developing and applying tools to characterize the complexity of protein interactions within the cell. Using cross-linking mass spectrometry (XL-MS) techniques, they chart the protein interactomes of complex biological systems in order to visualize how proteins are spatially organized and dynamically regulated in vivo..
Jesper Olsen, Vice Director, Novo Nordisk Foundation Center
Dr. Olsen is the Vice Director of the Novo Nordisk Foundation Center for Protein Research (CPR) at University of Copenhagen. His lab characterizes how signaling networks regulate cellular responses differentially when mediated by phosphorylation and other modifications. He has received a number of research awards including the Max Planck Institute for Biochemistry Junior Research Award and HUPO Young Investigator Award in Proteomic Sciences.
Reid Townsend, Professor, Washington University
Dr. Townsend is a Professor in the Department of Medicine within the Divisions of Metabolism and Oncology at Washington University in St. Louis, MO. He directs the Proteomics Shared Resource to support the programs of the Siteman Comprehensive Cancer Center and the Institute of Clinical and Translational Sciences. His research interests include: i) discovery and validation of new cancer biology that could translate into new clinical paradigms and drug targets, protein biomarker of neurological disease, and identifying functional post-translational modifications. His most recent interest is using discovery and targeted proteomics to enlighten the biology of the understudied kinases as part of the “Illuminating the the Druggable Genome” initiative.
Lan Huang, Professor of Physiology & Biophysics, University of California
Dr. Huang is a Professor of Physiology & Biophysics in the School of Medicine at the University of California in Irvine. Her research focuses on developing novel, integrated mass spectrometry-based proteomic strategies used to determine architectures of protein complexes and define PPI landscapes at the systems-level in vitro and in vivo and her lab has developed several quantitative cross-linking mass spectrometry strategies for comparative analysis of conformational changes in protein complexes.
Nick Seyfried, Associate Professor, Emory University School of Medicine
Dr. Seyfried is an Associate Professor in the Departments of Biochemistry and Neurology at Emory University School of Medicine. His research focuses on the integration of proteomics, transcriptomics, and systems biology to tackle fundamental questions related to the pathogenesis of Alzheimer’s Disease (AD) and other neurodegenerative disorders. His team utilizes both label-free and isobaric Tandem Mass Tag (TMT) quantitative mass spectrometry to identify and quantify proteins and post-translational modifications in human brain, plasma, and cerebrospinal fluid.
Steve Carr, Director of Proteomics, Broad Institute of MIT
Dr. Carr is Director of Proteomics at the Broad Institute of MIT and Harvard and a leader in the development of novel proteomics methodology and application in biology and medicine. Steve and his group collaborate with scientists throughout the Broad Institute community to focus on the discovery and quantitative verification of biomarkers for major diseases including cancer, cardiovascular and infectious diseases as well as pharmacodynamics markers of drug response.
Roman Fischer, Principle Investigator, University of Oxford
Dr. Fischer leads the Discovery Proteomics Facility and is a principal investigator at the University of Oxford. His lab focusses on proteomic strategies to access the deep proteome from minimal sample materials to detect protein isoforms and PTMs in the context of tumor biology and drug target. Dr. Fisher was a 2017 TMT Research Award recipient (Gold Level).
* Required field